NCT04765111View on ClinicalTrials.gov

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

53

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER